SLC5A2 and type 2 diabetes mellitus: Semaglutide appeared to reduce hsCRP ratios-to-baseline to a greater extent than comparators — another GLP-1RA (exenatide ER), an SGLT-2 inhibitor (empagliflozin), and placebo (not significant versus placebo in PIONEER 5) — in subjects with type 2 diabetes, and this was partially mediated via its effect on HbA1c and BW.